drug
GLATIRAMER ACETATE
Marketedupdated 3mo agoby Upsher-Smith Laboratories LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple sclerosis and neoplasm and 8 investigational indications.
all catalysts(27)
approval · 27
Apr 16, 2015
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Feb 12, 2018
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Nov 9, 2020
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Sep 21, 2022
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Sep 21, 2022
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Sep 21, 2022
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Sep 21, 2022
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
May 8, 2023
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Jul 5, 2023
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 19, 2024
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 19, 2024
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 7, 2025
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Mar 7, 2025
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Dec 31, 2025
approval
GLATIRAMER ACETATE — FDA approval
GLATIRAMER ACETATE
→
Feb 11, 2026
approval
GLATIRAMER ACETATE — FDA approval
GLATIRAMER ACETATE
→
Feb 11, 2026
approval
GLATIRAMER ACETATE — FDA approval
GLATIRAMER ACETATE
→
Feb 12, 2026
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Feb 12, 2026
approval
GLATOPA (GLATIRAMER ACETATE) — FDA approval
GLATIRAMER ACETATE
→
Trials studying GLATIRAMER ACETATE
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- —A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- phase3A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
- phase4A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- —Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
- phase2Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that